AbbVie Reports Third-Quarter 2026 Financial Results and Increases Dividend

AbbVie reported third-quarter 2026 net revenues of $17.404 billion and adjusted diluted EPS of $3.82, both above analyst consensus estimates. Strong performance in its immunology and neuroscience portfolios led the company to raise its full-year adjusted EPS guidance to $13.95–$13.99. The board increased the quarterly dividend 5.2%, from $1.73 to $1.82 per share, payable February 16, 2027. Management cited recent regulatory approvals and clinical data as support for the company’s long-term growth potential.